Comparative Pharmacology
Head-to-head clinical analysis: PARICALCITOL versus ZEMPLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARICALCITOL versus ZEMPLAR.
PARICALCITOL vs ZEMPLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor (VDR) in target tissues, including the parathyroid glands, kidneys, and intestines. It selectively activates VDR to suppress parathyroid hormone (PTH) secretion, reduce parathyroid cell proliferation, and modulate calcium and phosphate homeostasis with lower calcemic and phosphatemic effects compared to calcitriol.
Vitamin D receptor agonist; binds to vitamin D receptors, regulating gene expression of calcium-binding proteins and cellular proliferation/differentiation.
0.04 to 0.1 mcg/kg intravenously bolus no more frequently than every other day during dialysis, or 1 to 4 mcg orally once daily.
0.04-0.1 mcg/kg IV three times weekly; titrate to serum calcium. Oral: 1-2 mcg daily or 0.5-1 mcg three times weekly.
None Documented
None Documented
Clinical Note
moderateParicalcitol + Digoxin
"The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin."
Clinical Note
moderateParicalcitol + Hydrochlorothiazide
"Paricalcitol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateParicalcitol + Bendroflumethiazide
"Paricalcitol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateParicalcitol + Methyclothiazide
Terminal elimination half-life is approximately 5-7 hours in healthy subjects, but may be prolonged to 14-20 hours in patients with renal impairment.
Terminal elimination half-life is 5–7 hours in healthy subjects; prolonged to 14–21 hours in patients with chronic kidney disease stage 5 on hemodialysis, reflecting reduced clearance.
Primarily fecal (74%) via hepatobiliary excretion; renal elimination accounts for approximately 16% as unchanged drug.
Primarily hepatobiliary (74% of absorbed dose recovered in feces as parent drug and metabolites); renal excretion accounts for approximately 16% (primarily as metabolites).
Category C
Category C
Vitamin D Analog
Vitamin D Analog
"Paricalcitol may increase the hypercalcemic activities of Methyclothiazide."